iph4102
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02593045)
Timeline
Indications
Mechanism of action
Killer cell immunoglobulin-like receptor 3DL2 antagonist
KIR3DL2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297998 ↗
Also known as
- iph4102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05321147 | Phase 1 | Mar 17, 2022 | Innate Pharma |
| NCT04984837 | Phase 2 | Aug 30, 2021 | Innate Pharma, The Lymphoma Academic Research Organisation, The Lymphoma Study Association |
| NCT03902184 | Phase 2 | May 13, 2019 | Innate Pharma |
| NCT02593045 | Phase 1 | Oct 1, 2015 | Innate Pharma |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innate Pharma | For profit | 4 | 3 | 2 | 2015 |
| The Lymphoma Academic Research Organisation | Academic/Hospital | 1 | 1 | 1 | 2021 |
| The Lymphoma Study Association | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1